[YINSON] YoY Annual (Unaudited) Result on 31-Jan-2024 [#4]

Stock
[YINSON] YINSON HOLDINGS BHD
Announcement Date
22-Mar-2024
Admission Sponsor
-
Sponsor
-
Financial Year
31-Jan-2024
Quarter
31-Jan-2024 [#4]
Profit Trend
YoY- 64.51%
Quarter Report
Latest QR
Upcoming QR
YINSON's Result
YINSON's Financial Summary
View:
Show?
Annual (Unaudited) Result
31/01/24 31/01/23 31/01/22 31/01/21 31/01/20 31/01/19 31/01/18 CAGR
Revenue 11,646,000 6,324,000 3,607,000 4,849,000 2,519,340 1,034,899 910,156 52.90%
PBT 1,695,000 845,000 716,000 580,000 331,118 343,861 361,770 29.34%
Tax -553,000 -257,000 -192,000 -168,000 -69,821 -79,482 -69,697 41.20%
NP 1,142,000 588,000 524,000 412,000 261,297 264,379 292,073 25.50%
-
NP to SH 964,000 586,000 401,000 315,000 209,909 234,896 292,179 22.00%
-
Tax Rate 32.63% 30.41% 26.82% 28.97% 21.09% 23.11% 19.27% -
Total Cost 10,504,000 5,736,000 3,083,000 4,437,000 2,258,043 770,520 618,083 60.30%
-
Net Worth 5,435,824 4,141,914 2,332,792 1,780,219 1,645,192 1,751,680 1,970,282 18.41%
Dividend
31/01/24 31/01/23 31/01/22 31/01/21 31/01/20 31/01/19 31/01/18 CAGR
Div 87,205 57,928 63,912 63,960 66,249 65,688 129,163 -6.33%
Div Payout % 9.05% 9.89% 15.94% 20.30% 31.56% 27.96% 44.21% -
Equity
31/01/24 31/01/23 31/01/22 31/01/21 31/01/20 31/01/19 31/01/18 CAGR
Net Worth 5,435,824 4,141,914 2,332,792 1,780,219 1,645,192 1,751,680 1,970,282 18.41%
NOSH 3,064,331 3,053,682 1,101,346 1,099,519 1,094,745 1,093,245 1,092,808 18.74%
Ratio Analysis
31/01/24 31/01/23 31/01/22 31/01/21 31/01/20 31/01/19 31/01/18 CAGR
NP Margin 9.81% 9.30% 14.53% 8.50% 10.37% 25.55% 32.09% -
ROE 17.73% 14.15% 17.19% 17.69% 12.76% 13.41% 14.83% -
Per Share
31/01/24 31/01/23 31/01/22 31/01/21 31/01/20 31/01/19 31/01/18 CAGR
RPS 400.64 218.34 338.62 454.88 228.17 94.53 84.56 29.58%
EPS 28.50 16.60 37.60 29.50 18.90 21.43 26.85 0.99%
DPS 3.00 2.00 6.00 6.00 6.00 6.00 12.00 -20.62%
NAPS 1.87 1.43 2.19 1.67 1.49 1.60 1.8305 0.35%
Adjusted Per Share Value based on latest NOSH - 3,064,331
31/01/24 31/01/23 31/01/22 31/01/21 31/01/20 31/01/19 31/01/18 CAGR
RPS 363.37 197.31 112.54 151.29 78.61 32.29 28.40 52.90%
EPS 30.08 18.28 12.51 9.83 6.55 7.33 9.12 21.99%
DPS 2.72 1.81 1.99 2.00 2.07 2.05 4.03 -6.33%
NAPS 1.696 1.2923 0.7279 0.5554 0.5133 0.5465 0.6147 18.42%
Price Multiplier on Financial Quarter End Date
31/01/24 31/01/23 31/01/22 31/01/21 31/01/20 31/01/19 31/01/18 CAGR
Date 31/01/24 31/01/23 31/01/22 29/01/21 31/01/20 31/01/19 30/01/18 -
Price 2.57 2.69 5.50 5.20 6.20 4.10 4.22 -
P/RPS 0.64 1.23 1.62 1.14 2.72 4.34 4.99 -28.97%
P/EPS 7.75 13.30 14.61 17.60 32.61 19.11 15.55 -10.95%
EY 12.90 7.52 6.84 5.68 3.07 5.23 6.43 12.29%
DY 1.17 0.74 1.09 1.15 0.97 1.46 2.84 -13.73%
P/NAPS 1.37 1.88 2.51 3.11 4.16 2.56 2.31 -8.33%
Price Multiplier on Announcement Date
31/01/24 31/01/23 31/01/22 31/01/21 31/01/20 31/01/19 31/01/18 CAGR
Date 22/03/24 23/03/23 29/03/22 25/03/21 25/03/20 27/03/19 29/03/18 -
Price 2.45 2.42 4.49 5.40 5.09 4.59 3.76 -
P/RPS 0.61 1.11 1.33 1.19 2.23 4.86 4.45 -28.18%
P/EPS 7.39 11.96 11.93 18.27 26.77 21.39 13.85 -9.93%
EY 13.54 8.36 8.38 5.47 3.73 4.67 7.22 11.04%
DY 1.22 0.83 1.34 1.11 1.18 1.31 3.19 -14.79%
P/NAPS 1.31 1.69 2.05 3.23 3.42 2.87 2.05 -7.18%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment